Head and neck squamous cell carcinoma (HNSCC) demonstrates suboptimal responses to current immune checkpoint inhibitors (ICIs), with objective response rates (ORRs) of merely 15-20%. The molecular mechanisms underlying these low ORRs remain incompletely defined. Here, two functionally distinct CD8⺠T cell subsets are identified within the tumor microenvironment: precursor exhausted T (Tex(prog)) cells and terminally exhausted T (Tex(term)) cells. Notably, although anti-PD-1 therapy reduced Tex(prog) cell frequencies, it failed to reverse Tex(term) cells. Elevated Tex(term) cell infiltration correlated with advanced tumor-node-metastasis (TNM) staging and poor prognosis. Furthermore, non-responders exhibited significantly higher baseline Tex(term) proportions than responders before immunotherapy. Multivariate analysis established stromal Tex(term) cell density as both an independent prognostic factor and predictor of ICIs resistance. Mechanistically, Tex(term) cell infiltration strongly correlated with PD-L1 on tumor-derived extracellular vesicles (PD-L1(+)EVs). Most importantly, it is demonstrated that PD-L1(+)EVs drive Tex(term) cell differentiation by upregulating the basic leucine zipper transcription factor, ATF-like (BATF) in CD8⺠T cells. Knocking out PD-L1 on EVs reduced Tex(term) cell infiltration and BATF expression. These findings elucidate an EV-mediated immune evasion axis and reveal actionable targets to overcome immunotherapy resistance.
PD-L1 on Tumor-Derived Extracellular Vesicles Induces CD8(+) T Cell Terminal Exhaustion and Mediates Anti-PD-1 Resistance in Head and Neck Squamous Cell Carcinoma.
阅读:5
作者:Fang Ruihua, Huang Bixue, Li Yun, Cai Zhimou, Deng Yicheng, Cen Xiaoqing, Sun Wei, Zhang Jinhong, Xu Zhenglin, Guo Wenbin, Lyu Yi, Luo Shiyun, Chen Zhesheng, Lyu Kexing, Wen Weiping, Lei Wenbin
| 期刊: | Advanced Science | 影响因子: | 14.100 |
| 时间: | 2026 | 起止号: | 2026 Jan;13(4):e16348 |
| doi: | 10.1002/advs.202516348 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
